Price T Rowe Associates Inc. MD Has $127.45 Million Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Price T Rowe Associates Inc. MD trimmed its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,412,191 shares of the company's stock after selling 26,335 shares during the quarter. Price T Rowe Associates Inc. MD owned 3.37% of Biohaven worth $127,446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new position in Biohaven during the fourth quarter valued at approximately $56,000. Amalgamated Bank raised its position in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after acquiring an additional 527 shares in the last quarter. US Bancorp DE raised its position in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after acquiring an additional 798 shares in the last quarter. Elkhorn Partners Limited Partnership raised its position in Biohaven by 50.0% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares in the last quarter. Finally, KBC Group NV raised its position in Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after acquiring an additional 1,127 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Analysts Set New Price Targets

BHVN has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their price target on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Robert W. Baird lowered their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a report on Monday. William Blair upgraded Biohaven to a "strong-buy" rating in a report on Thursday, April 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $62.54.

Biohaven Price Performance

BHVN traded up $0.41 during mid-day trading on Thursday, hitting $22.53. The stock had a trading volume of 1,603,765 shares, compared to its average volume of 1,152,340. Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.70. The stock's fifty day simple moving average is $25.44 and its 200-day simple moving average is $36.98. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -2.41 and a beta of 1.33.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John W. Childs acquired 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now directly owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.